VCR ventracor limited

first aust. `artifical heart` trials will begin ea

  1. 5,609 Posts.
    First Aust. `Artifical Heart` Trials Will Begin Early 2003
    24/12/02 12:14:00 PM


    HOMEX - Brisbane

    Australian heart company, Ventracor Limited (ASX:VCR), has received
    approval to begin human clinical trials of its VentrAssist(TM)
    'artificial heart' device.

    Ventracor Managing Director and Chief Executive Officer, Mr Michael
    Spooner, said the Ethics Committee of The Alfred hospital in
    Melbourne approved a clinical Pilot Trial of about 10 implants after
    a detailed review of Ventracor's submission in November.

    Mr Spooner said in granting the approval, the Ethics Committee had
    requested a number of minor amendments and additions but he expected
    these would be resolved quickly.

    He said precise timing for the first 'artificial heart' implant was
    now in the hands of The Alfred hospital medical team, led by
    Professor Don Esmore, and the patients themselves.

    Mr Spooner said The Alfred was likely to now begin active recruitment
    of patients suffering end-stage congestive heart failure and that
    this process could take about 10 to 12 weeks.

    "This Pilot Trial will be an independent assessment and so the timing
    for commencement, patient recruitment, performing the surgical
    procedure and post-operative care will all be at the discretion of
    The Alfred hospital medical team.

    "Ventracor will assist Professor Esmore and his medical team wherever
    possible throughout the Trial process. At all times, Ventracor will
    undertake those actions necessary to ensure the confidentiality and
    wellbeing of patients and their families.

    "This first Pilot Trial in Melbourne will be a precursor to a larger
    multi-centre global Pivotal Trial in other leading hospitals in
    Australia, Europe and the United States in the second half of 2003.

    "Our goal is to get VentrAssist(TM) to global markets as early as is
    possible and start seeing the benefits flow to both doctors and

    "We have mapped out every element of the process, every aspect is
    being professionally managed, and the whole company remains totally
    focused and driven toward meeting every milestone before us", he

    Mr Spooner added Ventracor was well positioned to significantly
    improve the quality of life for hundreds of thousands of people
    worldwide suffering heart failure, by obtaining a significant share
    of the left ventricular assist device (LVAD) market, which is
    expected to grow to between $US7.5 billion and $US12 billion annually
    in the next few years.

    For further information, please contact:

    Michael Spooner Julie Meldrum
    02 9406 3100 02 9406 3100 or 0419 228 128

watchlist Created with Sketch. Add VCR (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.